Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients

被引:74
作者
Zhao, Qing-Tao [1 ]
Yang, Yong [2 ]
Xu, Shun [3 ]
Zhang, Xiao-Peng [1 ]
Wang, Hui-En [1 ]
Zhang, Hua [1 ]
Wang, Zhi-Kang [1 ]
Yuan, Zheng [1 ]
Duan, Guo-Chen [1 ]
机构
[1] Hebei Gen Hosp, Dept Thorac Surg, Shijiazhuang 050051, Hebei Province, Peoples R China
[2] China Med Univ, Sujiatun Cent Hosp, Dept Gen Surg, Shenyang, Liaoning, Peoples R China
[3] China Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Shenyang, Liaoning, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2015年 / 8卷
关键词
NLR; lung cancer; prognosis; meta-analysis; NEUTROPHIL/LYMPHOCYTE RATIO; PRETREATMENT NEUTROPHIL; INFLAMMATION; SURVIVAL; ASSOCIATION; STATISTICS; RESECTION; THERAPY; MARKER; IMPACT;
D O I
10.2147/OTT.S90875
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Neutrophil to lymphocyte ratio (NLR) has recently been reported to be a poor prognostic indicator in lung cancer. However, the prognostic value of the NLR in patients with lung cancer still remains controversial. We performed a meta-analysis to evaluate the prognostic value of NLR in patients with lung cancer. Methods: We performed a comprehensive literature search in PubMed, Ovid, the Cochrane Library, and Web of Science databases in May 2015. Studies were assessed for quality using the Newcastle-Ottawa Scale. Results: Twenty-two studies with a total of 7,054 patients were included in this meta-analysis. The meta-analysis was performed to generate combined hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS). Our analysis results indicated that high NLR predicted poorer OS (HR, 1.51; 95% confidence interval [CI], 1.33-1.71; P < 0.001) and PFS (HR, 1.33; 95% CI, 1.07-1.67; P = 0.012) in patients with lung cancer. High NLR was also associated with poor OS in lung cancer treated by surgical resection (HR, 1.59; 95% CI, 1.26-1.99; P < 0.001) and chemotherapy (HR, 1.15; 95% CI, 1.08-1.22; P < 0.001). In addition, NLR cut-off value = 5 (HR, 1.57; 95% CI, 1.16-2.12; P = 0.003) and NLR cut-off value <5 (HR, 1.47; 95% CI, 1.28-1.69; P < 0.001). Conclusion: This meta-analysis result suggested that NLR should have significant predictive ability for estimating OS and PFS in patients with lung cancer and may be as a significant biomarker in the prognosis of lung cancer.
引用
收藏
页码:2731 / 2738
页数:8
相关论文
共 48 条
  • [41] Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
    Teramukai, Satoshi
    Kitano, Toshiyuki
    Kishida, Yusuke
    Kawahara, Masaaki
    Kubota, Kaoru
    Komuta, Kiyoshi
    Minato, Koichi
    Mio, Tadashi
    Fujita, Yuka
    Yonei, Toshiro
    Nakano, Kikuo
    Tsuboi, Masahiro
    Shibata, Kazuhiko
    Furuse, Kiyoyuki
    Fukushima, Masanori
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1950 - 1958
  • [42] Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung Cancer
    Wang, Xinyue
    Jiang, Richeng
    Li, Kai
    [J]. CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 69 (03) : 633 - 640
  • [43] Prognostic Role of NLR in Urinary Cancers: A Meta-Analysis
    Wei, Yong
    Jiang, Ya-Zhi
    Qian, Wen-Hui
    [J]. PLOS ONE, 2014, 9 (03):
  • [44] Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
    Xiao, Wei-Kai
    Chen, Dong
    Li, Shao-Qiang
    Fu, Shun-Jun
    Peng, Bao-Gang
    Liang, Li-Jian
    [J]. BMC CANCER, 2014, 14
  • [45] The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer
    Yamanaka, Takeharu
    Matsumoto, Shigemi
    Teramukai, Satoshi
    Ishiwata, Ryota
    Nagai, Yoji
    Fukushima, Masanori
    [J]. ONCOLOGY, 2007, 73 (3-4) : 215 - 220
  • [46] Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy
    Yao, Yanwen
    Yuan, Dongmei
    Liu, Hongbing
    Gu, Xiaoling
    Song, Yong
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (03) : 471 - 479
  • [47] Yildirim M, 2013, J BUON, V18, P728
  • [48] Evaluation of Preoperative Hematologic Markers as Prognostic Factors and Establishment of Novel Risk Stratification in Resected pN0 Non-Small-Cell Lung Cancer
    Zhang, Tiehong
    Jiang, Yuanzhu
    Qu, Xiao
    Shen, Hongchang
    Liu, Qi
    Du, Jiajun
    [J]. PLOS ONE, 2014, 9 (10):